Please assess the completion status of the following clinical trial:

Trial Title: Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic leiomyosarcoma (uterus or soft tissue) in inoperable relapse with no previous chemotherapy~* At least one measurable lesion according to RECIST criteria before inclusion. At least one of the target is in a none irradiated area~* Aged \>/= 18 years and physiological age \</= 70 years~* PS \</= 2~* Normal hematological function (Polymorphonuclear Neutrophils \>/= 1500/mm3, platelets \>/= 100 000/mm3)~* Normal kidney function (creatinine \< 1.5xN)~* Creatinine phosphokinase \</= 2.5xN~* Normal hepatic function (total bilirubin \</= 1xN; transaminase \</= 2.5xN and alkaline phosphatase \</= 1.5xN)~* Cardiac function: normal echography and/or isotopic ventriculography (FR\>30%, FEVG \> 50%)~* Patients able to procreate must use a birth control device during treatment and during 3 months after treatment for women; 5 months for men~* Signed informed consent~* Patient under affiliated to a system of care~Exclusion Criteria:~* Any other histological type of uterus sarcoma (carcinosarcoma...) or soft tissue~* Specific contraindication to the treatment~* Previous or evolutive mental disease~* Previous cancer~* Symptomatic or known brain metastasis~* Previous radiotherapy ont he only measurable lesion~* Previous allograft or autograft~* Known positive serology (HIV, HbC, HbS)~* Pregnant or breastfeeding women~* Impossibility to follow the treatment for geographical, social or mental reason~* Patients under legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Soft tissue (Type: EXPERIMENTAL): None
- Uterus (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).